| Original language | English |
|---|---|
| Pages (from-to) | 85-89 |
| Number of pages | 5 |
| Journal | Blood |
| Volume | 134 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published or Issued - 4 Jul 2019 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Blood, Vol. 134, No. 1, 04.07.2019, p. 85-89.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission
AU - Shanmuganathan, Naranie
AU - Braley, Jodi A.
AU - Yong, Agnes S.M.
AU - Hiwase, Devendra K.
AU - Yeung, David T.
AU - Ross, David M.
AU - Hughes, Timothy P.
AU - Branford, Susan
N1 - Funding Information: N.S. received scholarship funding from the Royal Adelaide Hospital Research Foundation Dawes Scholarship. D.T.Y. is an Early Career Research Fellow of the National Health and Medical Research Council of Australia. S.B. received support from the National Health and Medical Research Council of Australia (APP1104425). T.P.H. received support from the National Health and Medical Research Council of Australia (APP1135949) and has the financial support of Cancer Council SA’s Beat Cancer Project on behalf of its donors and the State Government of South Australia through the Department of Health. Funding Information: Conflict-of-interest disclosure: N.S. received honoraria from Novartis and Bristol-Myers Squibb and travel and accommodation expenses from Novartis, Gilead, Amgen, and Janssen. A.S.M.Y. received research funding from Novartis, Bristol-Myers Squibb, and Celgene and honoraria from Novartis and Bristol-Myers Squibb. D.K.H. received honoraria from Novartis. D.T.Y. received research funding from Novartis and Bristol-Myers Squibb and honoraria from Pfizer, Amgen, Novartis, and Bristol-Myers Squibb. D.M.R. received research funding from Novartis and Celgene and honoraria from Novartis, Bristol-Myers Squibb, and Celgene. S.B. is a member of the advisory boards of Qiagen, Novartis, and Bristol-Myers Squibb and received honoraria from Qiagen, Novartis, Bristol-Myers Squibb, and Cepheid. T.P.H. holds a consultancy role in, and has received research funding and honoraria from, Novartis, Bristol-Myers Squibb, and Ariad. J.A.B. declares no competing financial interests.
PY - 2019/7/4
Y1 - 2019/7/4
UR - http://www.scopus.com/inward/record.url?scp=85069273822&partnerID=8YFLogxK
U2 - 10.1182/blood.2019000120
DO - 10.1182/blood.2019000120
M3 - Letter
C2 - 30967368
AN - SCOPUS:85069273822
SN - 0006-4971
VL - 134
SP - 85
EP - 89
JO - Blood
JF - Blood
IS - 1
ER -